Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
4.280
+0.140 (3.38%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Ironwood Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 389.32 | 296.15 | 351.41 | 442.74 | 410.6 | 413.75 | |
Revenue Growth | 26.19% | -15.72% | -20.63% | 7.83% | -0.76% | 6.22% |
Cost of Revenue | 88.69 | 95.14 | 111.42 | 104.79 | 44.27 | 70.41 |
Gross Profit | 300.62 | 201.02 | 239.99 | 337.95 | 366.33 | 343.35 |
Selling, General & Admin | 64.35 | 82.06 | 143.63 | 142.11 | 115.99 | 111.13 |
Operating Expenses | 64.35 | 82.06 | 143.63 | 142.11 | 115.99 | 111.13 |
Operating Income | 236.27 | 118.95 | 96.36 | 195.84 | 250.34 | 232.22 |
Interest Expense | -32.66 | -32.75 | -33.29 | -21.38 | -7.6 | -31.15 |
Interest & Investment Income | 5.67 | 4.08 | 4.47 | 18.97 | 9.5 | 0.73 |
Other Non Operating Income (Expenses) | 0.01 | - | 0.25 | -0.23 | 0.18 | -1.18 |
EBT Excluding Unusual Items | 209.29 | 90.28 | 67.79 | 193.2 | 252.42 | 200.61 |
Merger & Restructuring Charges | -1.91 | -20.26 | -2.59 | -45.82 | - | 0.04 |
Pretax Income | 207.38 | 70.03 | 65.2 | -948.07 | 252.42 | 200.66 |
Income Tax Expense | 77.51 | 46.01 | 64.32 | 83.49 | 77.36 | -327.79 |
Earnings From Continuing Operations | 129.87 | 24.02 | 0.88 | -1,032 | 175.07 | 528.45 |
Net Income to Company | 129.87 | 24.02 | 0.88 | -1,032 | 175.07 | 528.45 |
Minority Interest in Earnings | - | - | - | 29.32 | - | - |
Net Income | 129.87 | 24.02 | 0.88 | -1,002 | 175.07 | 528.45 |
Net Income to Common | 129.87 | 24.02 | 0.88 | -1,002 | 175.07 | 528.45 |
Net Income Growth | - | 2629.20% | - | - | -66.87% | 397.71% |
Shares Outstanding (Basic) | 163 | 162 | 159 | 155 | 154 | 162 |
Shares Outstanding (Diluted) | 166 | 163 | 160 | 155 | 186 | 164 |
Shares Change | 3.27% | 1.81% | 2.99% | -16.57% | 13.32% | 2.34% |
EPS (Basic) | 0.80 | 0.15 | 0.01 | -6.45 | 1.13 | 3.26 |
EPS (Diluted) | 0.79 | 0.15 | 0.01 | -6.45 | 0.96 | 3.21 |
EPS Growth | - | 2583.01% | - | - | -69.98% | 386.36% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 185.55 | 127.01 | 103.41 | 183.15 | 273.63 | 261.63 |
Free Cash Flow Per Share | 1.12 | 0.78 | 0.65 | 1.18 | 1.47 | 1.59 |
Gross Margin | 77.22% | 67.88% | 68.29% | 76.33% | 89.22% | 82.98% |
Operating Margin | 60.69% | 40.17% | 27.42% | 44.23% | 60.97% | 56.12% |
Profit Margin | 33.36% | 8.11% | 0.25% | -226.37% | 42.64% | 127.72% |
Free Cash Flow Margin | 47.66% | 42.89% | 29.43% | 41.37% | 66.64% | 63.23% |
EBITDA | 238.11 | 120.83 | 98.37 | 197.41 | 251.76 | 233.74 |
EBITDA Margin | 61.16% | 40.80% | 27.99% | 44.59% | 61.31% | 56.49% |
D&A For EBITDA | 1.84 | 1.88 | 2.01 | 1.58 | 1.42 | 1.52 |
EBIT | 236.27 | 118.95 | 96.36 | 195.84 | 250.34 | 232.22 |
EBIT Margin | 60.69% | 40.17% | 27.42% | 44.23% | 60.97% | 56.12% |
Effective Tax Rate | 37.38% | 65.70% | 98.65% | - | 30.65% | - |
Revenue as Reported | 389.32 | 296.15 | 351.41 | 442.74 | 410.6 | 413.75 |